<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="54263"><DrugName>bardoxolone methyl (oral, pulmonary arterial hypertension/ diabetic nephropathy), Reata/ Kyowa Hakko Kirin</DrugName><DrugNamesKey><Name id="42910112">bardoxolone</Name><Name id="42886140">bardoxolone methyl</Name></DrugNamesKey><DrugSynonyms><Name><Value>CDDO-Me</Value></Name><Name><Value>triterpenoid MMP inhibitor (capsule, cancer/mucositis/inflammation), Reata</Value></Name><Name><Value>RTA-402</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>bardoxolone methyl</Value><Types><Type>USAN</Type></Types></Name><Name><Value>NSC-713200</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>bardoxolone</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>bardoxolone (capsule, cancer/mucositis/inflammation), Reata</Value></Name><Name><Value>bardoxolone (capsule, cancer/mucositis/inflammation/kidney disease), Reata/ Kyowa Hakko Kirin/Abbott</Value></Name><Name><Value>bardoxolone (oral capsule, diabetic nephropathy), Reata/Abbott/Kyowa Hakko Kirin</Value></Name><Name><Value>bardoxolone methyl (oral, pulmonary arterial hypertension/ diabetic nephropathy), Reata/ Kyowa Hakko Kirin</Value></Name><Name><Value>218600-44-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>218600-53-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20565">Dartmouth College</CompanyOriginator><CompaniesPrimary><Company id="1003618">Reata Pharmaceuticals Inc</Company><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="1072507">AbbVie Inc</Company><Company id="13601">Abbott Laboratories</Company><Company id="20565">Dartmouth College</Company><Company id="23382">MD Anderson Cancer Center</Company></CompaniesSecondary><CrossReferences><SourceEntity id="54263" type="Drug"><TargetEntity id="284395" type="siDrug">Bardoxolone methyl</TargetEntity></SourceEntity><SourceEntity id="1003618" type="Company"><TargetEntity id="5000090491" type="organizationId">Reata Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1042596" type="Company"><TargetEntity id="4295877429" type="organizationId">Kyowa Kirin Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1072507" type="Company"><TargetEntity id="5037613143" type="organizationId">AbbVie Inc</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="20565" type="Company"><TargetEntity id="5000060085" type="organizationId">Dartmouth College</TargetEntity></SourceEntity><SourceEntity id="23382" type="Company"><TargetEntity id="4296619331" type="organizationId">University of Texas MD Anderson Cancer Center</TargetEntity></SourceEntity><SourceEntity id="100" type="ciIndication"><TargetEntity id="10061835" type="MEDDRA"></TargetEntity><TargetEntity id="D003928" type="MeSH"></TargetEntity><TargetEntity id="-271673667" type="omicsDisease"></TargetEntity><TargetEntity id="342" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1263" type="ciIndication"><TargetEntity id="D052016" type="MeSH"></TargetEntity><TargetEntity id="-834944241" type="omicsDisease"></TargetEntity><TargetEntity id="3438" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1867" type="ciIndication"><TargetEntity id="10037400" type="MEDDRA"></TargetEntity><TargetEntity id="D006976" type="MeSH"></TargetEntity><TargetEntity id="-104458654" type="omicsDisease"></TargetEntity><TargetEntity id="243" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2300" type="ciIndication"><TargetEntity id="D016891" type="MeSH"></TargetEntity><TargetEntity id="-2027891681" type="omicsDisease"></TargetEntity><TargetEntity id="1560" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"></TargetEntity><TargetEntity id="10033609" type="MEDDRA"></TargetEntity><TargetEntity id="D010190" type="MeSH"></TargetEntity><TargetEntity id="-670361033" type="omicsDisease"></TargetEntity><TargetEntity id="630" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3076" type="ciIndication"><TargetEntity id="10021263" type="MEDDRA"></TargetEntity><TargetEntity id="D005922" type="MeSH"></TargetEntity><TargetEntity id="-1551966656" type="omicsDisease"></TargetEntity><TargetEntity id="1804" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3077" type="ciIndication"><TargetEntity id="Q87.81" type="ICD10"></TargetEntity><TargetEntity id="759.89" type="ICD9"></TargetEntity><TargetEntity id="10001843" type="MEDDRA"></TargetEntity><TargetEntity id="D009394" type="MeSH"></TargetEntity><TargetEntity id="63" type="ORPHANET"></TargetEntity><TargetEntity id="-512052471" type="omicsDisease"></TargetEntity><TargetEntity id="2445" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3084" type="ciIndication"><TargetEntity id="10067757" type="MEDDRA"></TargetEntity><TargetEntity id="D005923" type="MeSH"></TargetEntity><TargetEntity id="-898159958" type="omicsDisease"></TargetEntity><TargetEntity id="1542" type="siCondition"></TargetEntity><TargetEntity id="5317" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3257" type="ciIndication"><TargetEntity id="10027480" type="MEDDRA"></TargetEntity><TargetEntity id="708" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3510" type="ciIndication"><TargetEntity id="I27.0" type="ICD10"></TargetEntity><TargetEntity id="10064911" type="MEDDRA"></TargetEntity><TargetEntity id="182090" type="ORPHANET"></TargetEntity><TargetEntity id="244" type="siCondition"></TargetEntity><TargetEntity id="2543" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="48829" type="Action"><TargetEntity id="3953" type="Mechanism">Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="2653" type="Action"><TargetEntity id="945" type="Mechanism">NF-kappaB (NFKB) Activation Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4476" type="Action"><TargetEntity id="1313" type="Mechanism">Inhibitory kappaB Kinase (IKK) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="19075" type="Action"><TargetEntity id="3245" type="Mechanism">STAT3 Expression Inhibitors</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="74" type="Action"><TargetEntity id="778" type="Mechanism">Antioxidants</TargetEntity></SourceEntity><SourceEntity id="PTGT-08848" type="ciTarget"><TargetEntity id="110005819498173" type="siTarget">Kelch-like ECH-associated protein 1</TargetEntity><TargetEntity id="2930" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="14">Sakigake</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="100">Diabetic nephropathy</Indication><Indication id="2300">Autosomal dominant polycystic kidney disease</Indication><Indication id="3076">IgA nephropathy</Indication><Indication id="3077">Alport syndrome</Indication><Indication id="3084">Focal segmental glomerulosclerosis</Indication><Indication id="3510">Pulmonary artery hypertension</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1263">Mucositis</Indication><Indication id="1867">Pulmonary hypertension</Indication><Indication id="188">Inflammatory disease</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="3257">Stage IV melanoma</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="48829">Kelch like ECH associated protein 1 modulator</Action><Action id="2653">Nuclear factor kappa B inhibitor</Action><Action id="19075">STAT3 gene inhibitor</Action><Action id="19519">NFE2L2 gene stimulator</Action><Action id="4476">I-kappa B kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1589">Apoptosis stimulator</Action><Action id="2953">Anti-inflammatory</Action><Action id="74">Antioxidant agent</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="61">Angiogenesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-07-01T11:30:06.000Z</LastModificationDate><ChangeDateLast>2019-06-07T00:00:00.000Z</ChangeDateLast><AddedDate>2005-10-12T14:50:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1003618" linkType="Company"&gt;Reata Pharmaceuticals&lt;/ulink&gt;, under license from &lt;ulink linkID="20565" linkType="Company"&gt;Dartmouth College&lt;/ulink&gt; and &lt;ulink linkID="23382" linkType="Company"&gt;The University of Texas MD Anderson Cancer Center&lt;/ulink&gt;, is developing the methyl ester of bardoxolone (RTA-402; CDDO-Me), an oral, pro-apoptotic, anti-inflammatory  and antiangiogenic synthetic triterpenoid IKK, STAT3 and NFkB inhibitor and activator of NFE2L2 (Nrf2), for the potential treatment  of pulmonary arterial hypertension (PAH), chronic kidney disease (CKD) caused by Alport syndrome and other rare renal diseases, and CKD caused by diabetes  [&lt;ulink linkID="1519397" linkType="Reference"&gt;1519397&lt;/ulink&gt;], [&lt;ulink linkID="1874501" linkType="Reference"&gt;1874501&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2016, a phase III study (CATALYST) was initiated in connective tissue disease-associated PAH (CTD-PAH) [&lt;ulink linkID="1799354" linkType="Reference"&gt;1799354&lt;/ulink&gt;]; in March 2018, Reata believed that results from this trial together with other data from the drug's program would be supportive of an NDA filing in this setting [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;]; in May 2018, following completion of sample size recalculation topline data were  expected in 1H20 [&lt;ulink linkID="2031888" linkType="Reference"&gt;2031888&lt;/ulink&gt;].  In March 2017,  a phase II/III trial (CARDINAL) for CKD caused by Alport syndrome was initiated [&lt;ulink linkID="1892509" linkType="Reference"&gt;1892509&lt;/ulink&gt;]; in July 2017, positive initial data from phase II portion were reported [&lt;ulink linkID="1947542" linkType="Reference"&gt;1947542&lt;/ulink&gt;]; In March 2017, accelerated approval in the US was expected in 1H19  for Alport syndrome [&lt;ulink linkID="1905672" linkType="Reference"&gt;1905672&lt;/ulink&gt;]; in March 2018, 1-year topline CARDINAL data supportive of accelerated approval were expected in 2H19 [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;]; in June 2019, the CARDINAL study was ongoing [&lt;ulink linkID="2159660" linkType="Reference"&gt;2159660&lt;/ulink&gt;]. In December 2017, Reata initiated the phase II  trial (PHOENIX) in rare forms of CKD, including autosomal dominant polycystic kidney disease (ADPKD), IgA nephropathy (IgAN), type 1 diabetic (T1D) CKD and focal segmental glomerulosclerosis (FSGS) [&lt;ulink linkID="1995262" linkType="Reference"&gt;1995262&lt;/ulink&gt;]; in May 2018, positive interim results for ADPKD and IgAN were presented [&lt;ulink linkID="2037519" linkType="Reference"&gt;2037519&lt;/ulink&gt;]; in September 2018, final data in IgAN and T1D CKD were reported  [&lt;ulink linkID="2076021" linkType="Reference"&gt;2076021&lt;/ulink&gt;]; in February 2019, positive final data  from the FSGS cohort were reported, showing that the primary endpoint  of improved kidney function was met   [&lt;ulink linkID="2121509" linkType="Reference"&gt;2121509&lt;/ulink&gt;]; in May 2019, a phase III trial (FALCON)  in ADPKD began  [&lt;ulink linkID="2157782" linkType="Reference"&gt;2157782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Asia licensee &lt;ulink linkID="1042596" linkType="Company"&gt;Kyowa Hakko Kirin&lt;/ulink&gt; is also developing the drug for CKD [&lt;ulink linkID="1067314" linkType="Reference"&gt;1067314&lt;/ulink&gt;], [&lt;ulink linkID="1133786" linkType="Reference"&gt;1133786&lt;/ulink&gt;]. In May 2018, Kyowa Hakko Kirin initiated a phase III trial (AYAME) in Japan in diabetes and CKD patients [&lt;ulink linkID="2040730" linkType="Reference"&gt;2040730&lt;/ulink&gt;], [&lt;ulink linkID="2041233" linkType="Reference"&gt;2041233&lt;/ulink&gt;]; Kyowa had decided to continue development in CKD and diabetes despite safety events in the BEACON trial conducted outside Japan [&lt;ulink linkID="1574402" linkType="Reference"&gt;1574402&lt;/ulink&gt;]. By June  2018, Kyowa Hakko Kirin was also conducting the phase III trial (CARDINAL)  in collaboration with  Reata   in Japan in  Alport syndrome patients [&lt;ulink linkID="2041233" linkType="Reference"&gt;2041233&lt;/ulink&gt;]. At the time, phase III development in Japan for diabetic kidney disease was expected to begin in 2019 [&lt;ulink linkID="2067192" linkType="Reference"&gt;2067192&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Reata was also previously developing the drug for the potential treatment  of cancer, including pancreatic cancer, therapy-induced mucositis and inflammatory disease, including rheumatoid arthritis (RA) [&lt;ulink linkID="627604" linkType="Reference"&gt;627604&lt;/ulink&gt;],  [&lt;ulink linkID="567993" linkType="Reference"&gt;567993&lt;/ulink&gt;], [&lt;ulink linkID="811461" linkType="Reference"&gt;811461&lt;/ulink&gt;], [&lt;ulink linkID="834208" linkType="Reference"&gt;834208&lt;/ulink&gt;], [&lt;ulink linkID="852967" linkType="Reference"&gt;852967&lt;/ulink&gt;], [&lt;ulink linkID="905520" linkType="Reference"&gt;905520&lt;/ulink&gt;], [&lt;ulink linkID="910180" linkType="Reference"&gt;910180&lt;/ulink&gt;]; however, by February 2012,  no further development had been reported for these indications [&lt;ulink linkID="1260932" linkType="Reference"&gt;1260932&lt;/ulink&gt;]. Reata had also planned to develop bardoxolone methyl for advanced melanoma, and a phase II trial in this indication was planned for 2007; however, this trial was withdrawn prior to recruitment [&lt;ulink linkID="835809" linkType="Reference"&gt;835809&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Reata and &lt;ulink linkID="13601" linkType="Company"&gt;Abbott&lt;/ulink&gt; were developing the drug in patients with CKD and type 2 diabetes; in  June 2011, the phase III BEACON trial began   [&lt;ulink linkID="1200759" linkType="Reference"&gt;1200759&lt;/ulink&gt;], but in October 2012, Reata informed Abbott that the trial was being discontinued following a recommendation regarding safety concerns due to excess serious adverse events and mortality in patients in the bardoxolone methyl arm [&lt;ulink linkID="1766937" linkType="Reference"&gt;1766937&lt;/ulink&gt;], and development for CKD and type 2 diabetes outside Japan was presumably discontinued.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In 1998, the original patent family containing claims to bardoxolone methyl and related compounds was filed and licensed to Reata in 2004. One granted US patent from this family, which contains claims covering bardoxolone methyl expires in 2022 not including patent term extension, and corresponding patents granted in Canada, Europe and Japan expires in 2019. The granted US patents covering specific forms of bardoxolone methyl, including the commercial form expires in 2028 or 2029 not including patent term extension, and two corresponding regional patents have been granted in Europe, with validation in multiple states scheduled for the second. Additional corresponding patents have been granted in Japan, China, Canada and several other countries; these granted foreign patents and pending patent applications, if granted, are due to expire in 2028. The most relevant granted US patents with composition of matter or method of use claims covering bardoxolone methyl are: &lt;ulink linkID="PA3071765" linkType="Patent"&gt;US-07863327&lt;/ulink&gt; (expires in April 2022) , &lt;ulink linkID="PA3683878" linkType="Patent"&gt;US-08034955&lt;/ulink&gt; (expires in June 2019), &lt;ulink linkID="PA3751731" linkType="Patent"&gt;US-08088824&lt;/ulink&gt; (expires in October 2029), &lt;ulink linkID="PA6800281" linkType="Patent"&gt;US-08309601&lt;/ulink&gt; (expires in August 2028), &lt;ulink linkID="PA5473500" linkType="Patent"&gt;US-08129429&lt;/ulink&gt; (expires in February 2030) and &lt;ulink linkID="PA7815217" linkType="Patent"&gt;US-08747901&lt;/ulink&gt; (expires in November 2030) [&lt;ulink linkID="1910389" linkType="Reference"&gt;1910389&lt;/ulink&gt;]. The patent covering specific formulations of bardoxolone methyl, including the commercial formulation, expires in 2030. Other granted patents and pending patent applications relating to specific uses of the drug, including the treatment of PH, PAH, and CKD, have expiration dates ranging from 2029 to 2034. The &lt;ulink linkID="PA7227725" linkType="Patent"&gt;US-08633243&lt;/ulink&gt; patent expires in  August 2028   [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In June 2019, the drug was granted Orphan Drug designation for the treatment of ADPKD   [&lt;ulink linkID="2159660" linkType="Reference"&gt;2159660&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2019, the company noted that the FDA had provided guidance that in the pivotal FALCON phase III trial in ADPKD, an analysis of retained eGFR demonstrating an improvement versus placebo after 1 year of bardoxolone treatment could support accelerated approval, while an improvement compared with placebo after 2 years could support full approval [&lt;ulink linkID="2157782" linkType="Reference"&gt;2157782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2018, Reata believed that the results from the CATALYST trial, together with other data from the bardoxolone methyl development program, would be sufficient to form the basis of an NDA submission to the FDA seeking approval of the drug for CTD-PAH [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, accelerated approval was expected in the US in 1H19  for Alport syndrome [&lt;ulink linkID="1905672" linkType="Reference"&gt;1905672&lt;/ulink&gt;]; in March 2018, Reata noted that the FDA had provided the company with guidance that, in patients with CKD caused by Alport syndrome, an analysis of the CARDINAL study regarding retained eGFR demonstrating an improvement versus placebo after 1 year of bardoxolone methyl treatment may support accelerated approval; additionally, data demonstrating an improvement versus placebo in retained eGFR after 2 years of treatment may support full approval [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, the  FDA granted Orphan Drug status for pancreatic cancer [&lt;ulink linkID="952903" linkType="Reference"&gt;952903&lt;/ulink&gt;]. In March 2015, the  FDA granted Orphan designation for PAH [&lt;ulink linkID="1647928" linkType="Reference"&gt;1647928&lt;/ulink&gt;]. In July 2017, the  FDA granted  Orphan designation for Alport syndrome [&lt;ulink linkID="1943942" linkType="Reference"&gt;1943942&lt;/ulink&gt;], [&lt;ulink linkID="1945224" linkType="Reference"&gt;1945224&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 2018, the COMP recommended granting bardoxolone methyl Orphan designation for treatment of Alport syndrome [&lt;ulink linkID="2028500" linkType="Reference"&gt;2028500&lt;/ulink&gt;]; in May 2018, the  EC granted  the drug Orphan designation for Alport syndrome [&lt;ulink linkID="2040411" linkType="Reference"&gt;2040411&lt;/ulink&gt;], [&lt;ulink linkID="2045345" linkType="Reference"&gt;2045345&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In March 2018, Sakigake designation was granted for the product for the treatment of diabetic nephropathy [&lt;ulink linkID="2017541" linkType="Reference"&gt;2017541&lt;/ulink&gt;], [&lt;ulink linkID="2017906" linkType="Reference"&gt;2017906&lt;/ulink&gt;], [&lt;ulink linkID="2018862" linkType="Reference"&gt;2018862&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Diabetic nephropathy&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In   May 2018, Kyowa Hakko Kirin initiated a multi-center, randomized, double-blind, placebo-controlled phase III trial (AYAME) of bardoxolone methyl in patients (expected n = 700) with diabetes and CKD  in Japan. The primary endpoint was time to onset of a ≥ 30% decrease in eGFR from baseline or ESRD. At that time, the study was expected to complete in March 2022 [&lt;ulink linkID="2040730" linkType="Reference"&gt;2040730&lt;/ulink&gt;], [&lt;ulink linkID="2041233" linkType="Reference"&gt;2041233&lt;/ulink&gt;]. In May 2019, the AYAME trial was ongoing [&lt;ulink linkID="2157782" linkType="Reference"&gt;2157782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, a pivotal, double-blind, randomized, phase III trial (BEACON; &lt;ulink linkID="77315" linkType="Protocol"&gt;NCT01351675&lt;/ulink&gt;; RTA 402-C-0903) was initiated in patients with CKD and type 2 diabetes in Austria, Australia, Belgium, Canada, Czech Republic, France, Germany, Israel, Italy, Mexico, Sweden, the UK and the US.   A total of 1600 subjects would be treated with 20 mg of a reformulated version of bardoxolone methyl or placebo once a day. The primary endpoint would be time-to-first-event composite consisting of progression to end-stage renal disease (defined as need for chronic dialysis or renal transplant) and cardiovascular death [&lt;ulink linkID="1200759" linkType="Reference"&gt;1200759&lt;/ulink&gt;]. By May 2012, the study was to complete at 300 events [&lt;ulink linkID="1293543" linkType="Reference"&gt;1293543&lt;/ulink&gt;], [&lt;ulink linkID="1293081" linkType="Reference"&gt;1293081&lt;/ulink&gt;]. In October 2012, however, Reata informed Abbott that the trial was being discontinued following a recommendation from the trial's Independent Data Monitoring Committee (IDMC) regarding safety concerns due to excess serious adverse events and mortality in patients in the bardoxolone methyl arm [&lt;ulink linkID="1766937" linkType="Reference"&gt;1766937&lt;/ulink&gt;]. In November 2013, the results were published and presented at the American Society of Nephrology's 2013 Annual Meeting in Atlanta, GA; BEACON  showed no significant difference between bardoxolone methyl and placebo groups in all-cause mortality but significantly higher incidence of heart failure events (heart failure hospitalization and deaths due to heart failure). The primary composite outcome (end-stage renal disease or cardiovascular death) did not demonstrate statistical significance  [&lt;ulink linkID="1498472" linkType="Reference"&gt;1498472&lt;/ulink&gt;]. In June 2014, data were presented at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Amsterdam, the Netherlands. The drug significantly increased eGFR , and reduced the likelihood of kidney failure outcomes, including composite of adjudicated end-stage renal disease, 30% decline or eGFR &amp;lt; 15 events (HR = 0.49) [&lt;ulink linkID="2011601" linkType="Reference"&gt;2011601&lt;/ulink&gt;], [&lt;ulink linkID="1574402" linkType="Reference"&gt;1574402&lt;/ulink&gt;]. In January 2018, data from a post-hoc analysis were published. Data from 2185 patients revealed an increase in eGFR from baseline for patients treat for at least 48 weeks, patients who received bardoxolone methyl were significantly less likely to experience a newly validated composite renal endpoint consisting of confirmed ≥30% decline from baseline in eGFR, confirmed eGFR &amp;lt;15 mL/min/1.73 m2, and end-stage renal disease events [&lt;ulink linkID="1998394" linkType="Reference"&gt;1998394&lt;/ulink&gt;], [&lt;ulink linkID="1998432" linkType="Reference"&gt;1998432&lt;/ulink&gt;]. In May 2018, similar data were presented at the ERA-EDTA meeting in Copenhagen, Denmark. Patients randomized to bardoxolone were 50% less likely than patients receiving placebo to experience events predicting kidney failure [&lt;ulink linkID="2037519" linkType="Reference"&gt;2037519&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By July 2014, Kyowa Hakko Kirin had decided to continue drug development following a detailed analysis of BEACON data and consultation with Japan's PMDA. At that time, an additional phase II trial was planned  [&lt;ulink linkID="1574402" linkType="Reference"&gt;1574402&lt;/ulink&gt;], [&lt;ulink linkID="1577812" linkType="Reference"&gt;1577812&lt;/ulink&gt;]. In December 2014, a randomized, open-label, double-blind, dose escalation, placebo controlled, parallel assignment, phase II study (&lt;ulink linkID="218465" linkType="Protocol"&gt;NCT02316821&lt;/ulink&gt;; RTA 402-005; TSUBAKI) was initiated in Japan, to assess the safety and efficacy of RTA-402 in stage 3 and 4 CKD patients (expected n = 72)  with non-insulin dependent diabetes who were not at risk for fluid retention. At that time, the trial was expected to complete in December 2017 [&lt;ulink linkID="1622693" linkType="Reference"&gt;1622693&lt;/ulink&gt;].  In May 2016, interim data from the  TSUBAKI trial were reported.  Data from interim analysis were assessed by an Independent Data Monitoring Committee  which demonstrated   a significant improvement in GFR   in the RTA-402 treated group compared with placebo  [&lt;ulink linkID="1765167" linkType="Reference"&gt;1765167&lt;/ulink&gt;]. In September 2017, the trial was completed [&lt;ulink linkID="2003511" linkType="Reference"&gt;2003511&lt;/ulink&gt;]. In November 2017, further data were presented at the ASN's Kidney Week 2017 in New Orleans, LA. A significantly improved eGFR was observed with bardoxolone methyl when compared with placebo (54.5 vs 47.7 mL/min at week 16). There were no changes in urinary creatinine excretion, urine output or sodium excretion, and no effect on BP. Overall, bardoxolone methyl was tolerated in patients with both stages of CKD tested [&lt;ulink linkID="1979511" linkType="Reference"&gt;1979511&lt;/ulink&gt;], [&lt;ulink linkID="2011601" linkType="Reference"&gt;2011601&lt;/ulink&gt;].     &lt;/para&gt;&lt;para&gt;In February  2012, a phase II trial was initiated in Japan in CKD patients [&lt;ulink linkID="1284851" linkType="Reference"&gt;1284851&lt;/ulink&gt;], [&lt;ulink linkID="1308643" linkType="Reference"&gt;1308643&lt;/ulink&gt;]. By October 2012, the study had been suspended [&lt;ulink linkID="1334787" linkType="Reference"&gt;1334787&lt;/ulink&gt;]. In November 2013, the trial was discontinued [&lt;ulink linkID="1498472" linkType="Reference"&gt;1498472&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2010, a randomized, open-label, phase II study (&lt;ulink linkID="63625" linkType="Protocol"&gt;NCT01053936&lt;/ulink&gt;; RTA 402-C-0902) was initiated in patients with type 2 diabetes and CKD (expected n = 56) in the US, to assess the safety, efficacy and pharmacodynamics of an amorphous dispersion formulation of bardoxolone methyl [&lt;ulink linkID="1071400" linkType="Reference"&gt;1071400&lt;/ulink&gt;]; in April 2011, the trial was completed [&lt;ulink linkID="1071400" linkType="Reference"&gt;1071400&lt;/ulink&gt;]; bardoxolone methyl improved  kidney function as measured by eGFR (increase of 6.5 eFRG ml/min/1.73mm2) [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By March 2009, a multicenter, 52-week, randomized, double-blind, parallel-assignment, safety and efficacy, phase IIb trial (&lt;ulink linkID="39033" linkType="Protocol"&gt;NCT00811889&lt;/ulink&gt;; RTA 402-C-0804; BEAM) had been initiated in 200 patients with advanced CKD and type 2 diabetes in the US. Subjects would receive 25, 75 or 150 mg of bardoxolone methyl once a day. The primary endpoint would be the change in glomerular filtration rate from baseline. Renal function, glycemic control and cardiovascular risk would also be assessed [&lt;ulink linkID="995067" linkType="Reference"&gt;995067&lt;/ulink&gt;], [&lt;ulink linkID="995007" linkType="Reference"&gt;995007&lt;/ulink&gt;]. In July 2010,  data from the phase IIb trial were reported. Data from two completed phase II trials showed that bardoxolone achieved  significant improvement in kidney function in patients with advanced CKD and type 2 diabetes. An increase from baseline in estimated glomerular filtration rate was observed in 90% of patients; more than 70% of patients classified as stage 4 CKD  at baseline improved to stage 3 CKD. Significant improvements were also seen in other markers of kidney function, glycemic control, and cardiovascular disease [&lt;ulink linkID="1115543" linkType="Reference"&gt;1115543&lt;/ulink&gt;]. In November 2010, further data from the BEAM trial were to be presented later that month at the American Society of Nephrology Renal Week Conference in Denver, CO [&lt;ulink linkID="1147471" linkType="Reference"&gt;1147471&lt;/ulink&gt;]. In November 2010, results were presented at the meeting which showed  at 24 weeks, 60% of the bardoxolone methyl group had a reduction in  disease severity compared with 17% of the placebo group. In each bardoxolone methyl group, 4% of patients showed worsening of stage of disease compared with 13% of the placebo group. There was also a mean increase of &amp;gt; 10 ml/min/1.72m2 in estimated GFR in bardoxolone methy-treated patients but  no change in those on placebo. Estimated GFR improved by 10% or more in 75% of patients on bardoxolone methyl, including 25% who experienced an improvement of 50% or more, compared with less than 2% in the placebo group [&lt;ulink linkID="1149417" linkType="Reference"&gt;1149417&lt;/ulink&gt;]. In June 2011, final data were both published and presented  at the 2011 European Renal Association-European Dialysis and Transplant Association Congress in Prague, Czech Republic. At 52 weeks, estimated GFR  was significantly improved with bardoxolone methyl treatment by up to 10.5 mL/min/1.73m2 in patients receiving 75 mg. Patients in the 25, 75 and 150 mg groups showed an average increase in estimated GFR  of 5.8, 10.5 and 9.3 mL/min/1.73m2, respectively, compared with placebo [&lt;ulink linkID="1203075" linkType="Reference"&gt;1203075&lt;/ulink&gt;], [&lt;ulink linkID="1203361" linkType="Reference"&gt;1203361&lt;/ulink&gt;]. In May 2012, clinical data were presented at the 33rd National Medicinal Chemistry Symposium in Tuscon, AZ. Bardoxolone improved the estimated glomerular filtration rate for at least 4 weeks post-treatment [&lt;ulink linkID="1293543" linkType="Reference"&gt;1293543&lt;/ulink&gt;], [&lt;ulink linkID="1293081" linkType="Reference"&gt;1293081&lt;/ulink&gt;]. Bardoxolone methyl improved  kidney function as measured by eGFR (increase of 8.6 eFRG ml/min/1.73mm2) [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, the company initiated an open-label, randomized, uncontrolled, single-group, dose-ranging phase IIa trial (&lt;ulink linkID="11040" linkType="Protocol"&gt;NCT00664027&lt;/ulink&gt;; RTA 402-C-0801) to determine the effects of bardoxolone methyl on renal function in patients with diabetic nephropathy (estimated n = 60). The primary endpoint was the effect of the three bardoxolone methyl doses (25, 75 or 150 mg po) on glomerular filtration rate, as measured by the both plasma and renal clearance of non-radioactive iohexol. Recruitment was ongoing at that time [&lt;ulink linkID="905520" linkType="Reference"&gt;905520&lt;/ulink&gt;], [&lt;ulink linkID="915117" linkType="Reference"&gt;915117&lt;/ulink&gt;]. In June 2009, data from the trial were presented at the 69th ADA scientific sessions in New Orleans, LA. The primary endpoint of change in estimated glomerular filtration rate at day 28 was met with an 88% response rate; the 75 mg dose resulted in a 28.5% change. Creatinine clearance, cystatin c, and uric acid were improved and Nrf2 was significantly induced. Glycemic control was improved with a mean decrease of 0.28% in HbA1c from baseline; in 35 patients with HbA1c ≥ 7% HbA1c decreased by 0.5%. Reductions in HbA1c were generally dose-dependent. Fasting plasma glucose and glucose disposal rate were also improved. The drug was tolerated [&lt;ulink linkID="1016074" linkType="Reference"&gt;1016074&lt;/ulink&gt;], [&lt;ulink linkID="1013402" linkType="Reference"&gt;1013402&lt;/ulink&gt;], [&lt;ulink linkID="1016074" linkType="Reference"&gt;1016074&lt;/ulink&gt;], [&lt;ulink linkID="1013450" linkType="Reference"&gt;1013450&lt;/ulink&gt;]. Bardoxolone methyl improved  kidney function as measured by eGFR (increase of 6.7 and 7.2  eFRG ml/min/1.73mm2 in Stratum 1 and Stratum 2, respectively) [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In April 2012, a multiple-dose, open-label, phase I trial (&lt;ulink linkID="85515" linkType="Protocol"&gt;NCT01549769&lt;/ulink&gt;; 402-C-1102) began in the US to assess pharmacokinetics and pharmacodynamics of bardoxolone methyl in patients with CKD and type 2 diabetes. In October 2013, the trial was completed. In April 2014, the study was listed as being terminated due to IDMC recommendation for safety concerns  [&lt;ulink linkID="2054600" linkType="Reference"&gt;2054600&lt;/ulink&gt;]; bardoxolone methyl improved  kidney function as measured by eGFR (increase of 9 eFRG ml/min/1.73mm2) [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February  2012, an US, 24-week, multicenter, randomized, double-blind, exploratory, phase I trial (&lt;ulink linkID="83627" linkType="Protocol"&gt;NCT01500798&lt;/ulink&gt;; 402-C-1005) to assess pharmacodynamics of bardoxolone methyl in patients (expected n = 18) with CKD and type 2 diabetes was  initiated and expected to be completed in June 2012 [&lt;ulink linkID="1260982" linkType="Reference"&gt;1260982&lt;/ulink&gt;]. By October 2014, the trial had been terminated due following an IDMC recommendation for safety concerns [&lt;ulink linkID="1260982" linkType="Reference"&gt;1260982&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Alport syndrome&lt;/subtitle&gt;In October 2016,   the company met FDA to discuss an  IND submission with a design for a phase II/III study, and the FDA guided the company to register   the study as single  pivotal trial. At that time, the company was planning an international, multicenter, double blind, randomized, placebo controlled trial in patients aged from 12 to 60 years with CKD caused by Alport syndrome having   eGFR values between 30 to 90 ml/min/1.73 m2 [&lt;ulink linkID="1874501" linkType="Reference"&gt;1874501&lt;/ulink&gt;]. In March 2017, the  phase II/III trial (&lt;ulink linkID="285085" linkType="Protocol"&gt;NCT03019185&lt;/ulink&gt;; RTA 402-C-1603; CARDINAL) was initiated in patients (expected n = 210) with Alport syndrome and no increased risk of fluid retention in the US, Europe, Australia, Canada and Japan. The study was to complete in January 2020  [&lt;ulink linkID="1892509" linkType="Reference"&gt;1892509&lt;/ulink&gt;]. In February 2017, patient screening was initiated in the trial [&lt;ulink linkID="1902994" linkType="Reference"&gt;1902994&lt;/ulink&gt;]. In March 2017, the first patient was enrolled in the phase II portion of the trial. In May 2017,  phase III one-year withdrawal data were expected  in 1H19  [&lt;ulink linkID="1926902" linkType="Reference"&gt;1926902&lt;/ulink&gt;]. In July 2017, initial data from the 30-patient, open-label, phase II portion of the trial were reported. The drug significantly improved kidney function as measured by eGFR.  A  mean improvement of eGFR   by 6.9 ml/min/1.73 m2 (n=19; p&amp;lt;0.0005) at week 4 which increased to 12.7 ml/min/1.73 m2 (n=8; p&amp;lt;0.00005) at week 12 from a baseline of 54.7 ml/min/1.73 m2, was observed. Over 80% of patients demonstrated improvement in eGFR of at least 3.0 ml/min/1.73 m2 by week 8, and the 95% confidence interval at week 12 was 7.9 ml/min/1.73 m2 to 17.5 mL/min/1.73 m2. Treatment effect surpassed the threshold of 3.0 mL/min/1.73 m2. At that time, screening of patients for phase III portion (n = 150) of the trial was initiated, and study results expected during 2H19 [&lt;ulink linkID="1947542" linkType="Reference"&gt;1947542&lt;/ulink&gt;]. In August 2017, the first patient was being enrolled in the phase III portion of the trial [&lt;ulink linkID="1951354" linkType="Reference"&gt;1951354&lt;/ulink&gt;]. In November 2017, further phase II data were presented at the ASN's Kidney Week 2017 in New Orleans, LA. eGFR improvements were associated with mean decreases in blood urea nitrogen, uric acid, and phosphorous. Increase in median UACR was observed, however, UACR/eGFR ratios were unchanged from baseline. All patients demonstrated eGFR increases  from baseline; 87% of patients demonstrated increases of at least 4 ml/min/1.73 m2, and 63% of patients demonstrated increases of at least 10 ml/min/1.73 m2. Further, 73% of patients had an improvement in CKD stage and none worsened. BP remained unchanged. Muscle spasm was the most common adverse events reported. Treatment was tolerated with no reports of discontinuations, serious adverse events [&lt;ulink linkID="1979499" linkType="Reference"&gt;1979499&lt;/ulink&gt;], [&lt;ulink linkID="1978142" linkType="Reference"&gt;1978142&lt;/ulink&gt;], [&lt;ulink linkID="1978612" linkType="Reference"&gt;1978612&lt;/ulink&gt;], [&lt;ulink linkID="2011601" linkType="Reference"&gt;2011601&lt;/ulink&gt;].     In March 2018,  one-year topline data regarding retained eGFR and supportive for accelerated approval were expected in 2H19.  Reata noted that the FDA had provided the company with guidance that, in patients with CKD caused by Alport syndrome, an analysis of the CARDINAL study regarding retained eGFR demonstrating an improvement versus placebo after one year of bardoxolone methyl treatment may support accelerated approval; additionally, data demonstrating an improvement versus placebo in retained eGFR after two years of treatment may support full approval [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;]. By April 2018, the trial was also recruiting in Australia, Europe and Japan, and was expected to recruit in Canada [&lt;ulink linkID="1892509" linkType="Reference"&gt;1892509&lt;/ulink&gt;]. In April 2018, results from the phase II portion of the trial were reported. The mean improvement form baseline in eGFR at week 36 was 11.3 ml/min/1.73 m2 (n = 27; p&amp;lt;0.0000001), with no significant changes from Week 12. No drug-related serious adverse events were reported [&lt;ulink linkID="2021774" linkType="Reference"&gt;2021774&lt;/ulink&gt;]. In May 2018, enrollment in the phase III portion of the trial was to complete in 2H18, with topline data expected in 2H19 [&lt;ulink linkID="2031888" linkType="Reference"&gt;2031888&lt;/ulink&gt;]. By  June 2018, Kyowa Hakko Kirin was also collaborating the trial in Japan [&lt;ulink linkID="2041233" linkType="Reference"&gt;2041233&lt;/ulink&gt;]. In July 2018, positive one-year results were reported from the phase II portion of the study; a significantly increased eGFR from baseline (n = 25) was observed at week 48 of 10.4 ml/min/1.73m2  (p&amp;lt;0.0001). A retained eGFR benefit of a mean of 4.1 ml/min/1.73m2 was observed at week 52 after withdrawal of active drug for four weeks  (p&amp;lt;0.05). No treatment-related serious AEs were reported [&lt;ulink linkID="2056428" linkType="Reference"&gt;2056428&lt;/ulink&gt;]; in October 2018, similar data were presented at the 2018 ASN Kidney Week in San Diego, CA [&lt;ulink linkID="2085188" linkType="Reference"&gt;2085188&lt;/ulink&gt;], [&lt;ulink linkID="2087693" linkType="Reference"&gt;2087693&lt;/ulink&gt;]. In November 2018, enrollment in the trial was completed with 157 patients [&lt;ulink linkID="2091836" linkType="Reference"&gt;2091836&lt;/ulink&gt;]. In April 2019, further data from phase II portion were presented at the 2019 World Congress of Nephrology in Melbourne, Australia. Significant increase in estimated glomerular filtration rate was observed in patients with Alport syndrome after 12 weeks of bardoxolone methyl treatment and improvements were maintained for up to 48 weeks (+10.4 mL/min/1.73m2; p&amp;lt;0.0001). At week-4 post-drug withdrawal, bardoxolone methyl resulted in a significant retained benefit of + 4.1 mL/min/1.73m2. There was no significant difference in urinary albumin to creatinine ratios from baseline at Weeks 48 or 52 [&lt;ulink linkID="2152699" linkType="Reference"&gt;2152699&lt;/ulink&gt;]. In May 2019, the CARDINAL trial was ongoing [&lt;ulink linkID="2157782" linkType="Reference"&gt;2157782&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rare chronic kidney diseases&lt;/subtitle&gt;In January 2019, the company announced the completion of an end-of-phase II meeting with the  FDA regarding the design of a phase III trial in ADPKD. The double-blind, placebo-controlled, parallel group, phase III trial  in patients (expected n = 300) aged 18 to 70 years  with an estimated glomerular filtration rate (eGFR) between 30 to 90 ml/min/1.73 m2. The primary efficacy endpoint was  change from baseline in eGFR compared to placebo after 48 weeks of treatment followed by a 4-week drug withdrawal period, the retained eGFR benefit. At that time, trial enrollment was expected to initiate in mid-2019 [&lt;ulink linkID="2108169" linkType="Reference"&gt;2108169&lt;/ulink&gt;],  In April 2019, the international,randomized,  sequential-assignment, triple, phase III trial (&lt;ulink linkID="377260" linkType="Protocol"&gt;NCT03918447&lt;/ulink&gt;; 402-C-1808; FALCON) was planned to begin in June 2019 to assess the  safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. At that time, the study was expected to complete in March 2023 [&lt;ulink linkID="2150409" linkType="Reference"&gt;2150409&lt;/ulink&gt;]. In May 2019, the first  patient was enrolled in the pivotal trial [&lt;ulink linkID="2157782" linkType="Reference"&gt;2157782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, an open-label, non-randomized, parallel group, multi-center phase II trial (&lt;ulink linkID="322109" linkType="Protocol"&gt;NCT03366337&lt;/ulink&gt;; 402-C-1702; PHOENIX) was  initiated in the US, in patients (n = 103) with rare CKD associated with T1D, IgAN, FSGS, and ADPKD, to assess the safety, tolerability, and efficacy of bardoxolone methyl. The primary endpoint was the increase in eGFR from baseline at week 12. At that time, the trial was expected to complete in August 2019 [&lt;ulink linkID="1995262" linkType="Reference"&gt;1995262&lt;/ulink&gt;]. By February 2018, at least one patient had been enrolled in each cohort [&lt;ulink linkID="2008820" linkType="Reference"&gt;2008820&lt;/ulink&gt;]. In May 2018, enrollment in all three cohorts was to be completed by the end of that month. At that time, primary endpoint data from CKD associated with T1D, IgAN and ADPKD were expected in 3Q18, and data from the FSGS cohort were planned in 1H19 [&lt;ulink linkID="2031888" linkType="Reference"&gt;2031888&lt;/ulink&gt;]. In May 2018, positive interim data were presented at the ERA-EDTA meeting in Copenhagen, Denmark. In the ADPKD cohort (n = 31) bardoxolone improved kidney function at week 3 (eGFR mean increase from baseline 6.6 ml/min/1.73 m2; p &amp;lt; 0.0001). In the nephropathy cohort (n = 26), bardoxolone also improved eGFR at week 4 (mean increase from baseline 8.4 ml/min/1.73 m2; p &amp;lt; 0.0001). No drug-related serious adverse events were reported [&lt;ulink linkID="2037519" linkType="Reference"&gt;2037519&lt;/ulink&gt;]. In July 2018, further positive results were reported from 31 patients in the ADPKD cohort showing a  significantly increased eGRF from baseline at week 12 of 9.3 ml/min/1.73m2 (p&amp;lt;0.0001) with bardoxolone treatment [&lt;ulink linkID="2056428" linkType="Reference"&gt;2056428&lt;/ulink&gt;]. In September 2018, final results were reported showing in the IgAN cohort, patients treated with bardoxolone experienced an increase in eGFR of 8.0 ml/min/1.73 m2 (p&amp;lt;0.0001) at week 12 compared with baseline, which represented a recovery of approximately six years of average eGFR loss. In the T1D CKD cohort, patients treated with bardoxolone experienced an increase in eGFR of 5.5 ml/min/1.73 m2 (p=0.02) at week 12 compared with baseline, which represented a recovery of approximately three years of average eGFR loss [&lt;ulink linkID="2076021" linkType="Reference"&gt;2076021&lt;/ulink&gt;].  In October 2018, further data were presented at the 2018 ASN Kidney Week in San Diego, CA. A total of 27 patients had increased eGFR by week-12. Despite the large increase in eGFR, bardoxolone methyl did not change urinary albumin. During the treatment, BP was stable and within normal limits. During the study, there was no evidence of overt fluid retention and no significant weight increases [&lt;ulink linkID="2085155" linkType="Reference"&gt;2085155&lt;/ulink&gt;]. Further clinical data were presented at the same conference. At week 4 and 12, the change in eGFR from baseline was 5.6 (p &amp;lt; 0.001) and 5.5 (p = 0.02), respectively. Lower treatment effect and higher variability was observed in subset of patients with near-normal eGFR at baseline (&amp;gt;/= 80 ml/min). Despite increase in eGFR, bardoxolone methyl treatment did not change urinary albumin. Stable and within normal limits of BP was observed during treatment. Evidence of over fluid and significant weight increases during study were not observed. Slight reduction in weight was observed [&lt;ulink linkID="2085161" linkType="Reference"&gt;2085161&lt;/ulink&gt;]. In February 2019, final results from the FSGC cohort of PHOENIX were reported showing that the primary endpoint of improved kidney function, as measured by patients' eGFR at week 12, was met. Patients in the treatment group reported an increase in eGFR of 7.8 ml/min/1.73 m2 (p&amp;lt;0.003) compared with baseline, representing a recovery of three years of  average eGFR loss. No treatment-emergent SAEs were reported. Mean systolic and diastolic blood pressure was reduced by 3.8 and 2.8 mmHG (p&amp;lt;0.0002 and p&amp;lt;0.6) respectively.  Urinary albumin excretion was unchanged after bardoxolone treatment [&lt;ulink linkID="2121509" linkType="Reference"&gt;2121509&lt;/ulink&gt;].  &lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;subtitle&gt;Pulmonary arterial hypertension&lt;/subtitle&gt;In October 2015, an end of phase II meeting with the FDA was completed and at that time, 	Reata was planning an initial phase III study in connective tissue disease-associated PAH (CTD-PAH) patients   in 2016 and    additional studies in other subtypes of PAH [&lt;ulink linkID="1706972" linkType="Reference"&gt;1706972&lt;/ulink&gt;]. In September 2016, the  international, double-blind, randomized, placebo-controlled phase III trial ((&lt;ulink linkID="251101" linkType="Protocol"&gt;NCT02657356&lt;/ulink&gt;; RTA 402-C-1504; CATALYST) ) began in CTD-PAH patients  (expected n = 220) in the US, Argentina, Australia, Belgium, Brazil, Canada, Chile, the Czech Republic, Germany, Israel, Japan, Mexico, the Netherlands, Philippines, Spain and the UK, and data were expected  during 1H18 [&lt;ulink linkID="1787648" linkType="Reference"&gt;1787648&lt;/ulink&gt;], [&lt;ulink linkID="1799354" linkType="Reference"&gt;1799354&lt;/ulink&gt;]. In October 2016, first patient was enrolled in the trial, which would  evaluate the drug when added to vasodilator therapy. Patients were to start at the 5 mg dose and dose-escalate to 10 mg at week 4. The primary endpoint is change in 6MWT relative to placebo at week 24 [&lt;ulink linkID="1804961" linkType="Reference"&gt;1804961&lt;/ulink&gt;]. The trial was expected to enroll between 130 and 200 patients  [&lt;ulink linkID="1905672" linkType="Reference"&gt;1905672&lt;/ulink&gt;].  In June 2017, recruitment was ongoing and the trial was expected to complete in May 2018 [&lt;ulink linkID="1799354" linkType="Reference"&gt;1799354&lt;/ulink&gt;]. In July 2017, data were expected during 2H18 [&lt;ulink linkID="1947542" linkType="Reference"&gt;1947542&lt;/ulink&gt;]. In March 2018, the company expected the data report timing could be changed, based on a pending sample size recalculation in 2Q18 [&lt;ulink linkID="2010061" linkType="Reference"&gt;2010061&lt;/ulink&gt;]. By May 2018, sample size recalculation had been performed in a blinded fashion, and indicated that 200 patients would be sufficient to  preserve statistical power of the trial. Consequently, it would require at least 12 months to complete enrollment and topline data were then expected during 1H20 [&lt;ulink linkID="2031888" linkType="Reference"&gt;2031888&lt;/ulink&gt;]; in May 2019, the CATALYST trial was ongoing [&lt;ulink linkID="2157782" linkType="Reference"&gt;2157782&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2014, a randomized, double-blind, parallel-group, phase II dose ranging study (&lt;ulink linkID="167602" linkType="Protocol"&gt;NCT02036970&lt;/ulink&gt;; RTA 402-C-1302; LARIAT) to  evaluate safety and efficacy of bardoxolone methyl in patients with PAH  (expected n = 112) was initiated in the US and Europe. The primary endpoint was the change from baseline in 6-minute walk distance (6MWD) at 16 weeks. At that time, the study was expected to complete in June 2015. LARIAT was a basket trial to evaluate bardoxolone  in patients with pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH [&lt;ulink linkID="1519397" linkType="Reference"&gt;1519397&lt;/ulink&gt;]. In October 2015, initial data from cohort 1 of the trial (patients with both idiopathic PAH (I-PAH) and CTD-PAH) were presented at the annual meeting of the 2015 American College of Chest Physicians (CHEST)  in Montreal, Canada.   Efficacy analysis showed that bardoxolone methyl increased 6MWD at doses of 2.5 to 10 mg through 16 weeks of treatment. A significant mean increase in 6MWD compared to baseline of 22 m and a placebo-corrected difference of 21.4 m (p = 0.037) was observed.  Changes in 6MWD were associated with improvements in metabolic parameters, including mean weight loss of 3 kg relative to placebo and reductions in creatine kinase. In the cohort of patients with CTD-PAH, there was a mean increase from baseline in 6MWD of 30 m and a placebo-corrected change of 44 m. At that time the trial was expanded to include a cohort of additional CTD-PAH patients    [&lt;ulink linkID="1706972" linkType="Reference"&gt;1706972&lt;/ulink&gt;], [&lt;ulink linkID="1725808" linkType="Reference"&gt;1725808&lt;/ulink&gt;]. In January 2016, the  trial was expanded to include patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD); the first patient was enrolled at that time [&lt;ulink linkID="1724894" linkType="Reference"&gt;1724894&lt;/ulink&gt;].  In June 2016, interim data from the extension phase of the trial were reported. The increase in 6MWD through 16 weeks of treatment that was previously reported was sustained through 32 weeks of treatment and was not significantly different from that at week 16 in the same set of patients. Bardoxolone methyl was well-tolerated, and fewer adverse events were reported during the extension trial [&lt;ulink linkID="1775512" linkType="Reference"&gt;1775512&lt;/ulink&gt;].  In October 2016, updated interim data were reported. In all patients with CTD-PAH (n = 22), bardoxolone methyl demonstrated a  significant mean time-averaged increase in 6MWD compared to baseline of 26.7 m, compared to a non-significant time-averaged mean change from baseline in 6MWD of 0.6 m for placebo. An analysis excluding three patients enrolled with anemia at screening (the enrollment criteria for the CATALYST trial) demonstrated a  significant mean time-averaged increase in 6MWD compared to baseline of 30.2 m, and placebo-treated patients had a non-significant mean change from baseline in 6MWD of –10.1 m [&lt;ulink linkID="1804961" linkType="Reference"&gt;1804961&lt;/ulink&gt;]. In November 2016, further clinical data were presented at the 80th ACR Annual Meeting in Washington DC. At week 32, 6MWD was 24.5 m for bardoxolone methyl patients randomized to active in part-1 at doses 2.5, 5 and 10 mg. Patients treated with bardoxolone methyl showed &amp;gt;/= 20 m 6MWD sustained between week 16 and 32. An average decrease in the weight from baseline of - 3.4 kg and a median decline in creatine kinase of - 28.0% at week 32 was observed in patients randomized to bardoxolone methyl at day 1 in part-2 [&lt;ulink linkID="1874089" linkType="Reference"&gt;1874089&lt;/ulink&gt;]. In May 2017, further interim data from the expanded cohort of PAH-CTD patients (n = 22) were presented at the 2017 ATS International Conference in Washington DC.  In the overall and CATALYST-eligible patient groups (patients without anemia at screening), the change in time-averaged 6MWD from baseline in placebo group was 0.6 and -10.1 m, respectively (p = 0.96 and 0.39, respectively; n = 7 and 5, respectively); and 26.7 and 30.2 m in bardoxolone methyl treatment group, respectively (each p &amp;lt; 0.001; n = 15 and 14, respectively); and the placebo-corrected change in time-averaged 6MWD in bardoxolone methyl treatment group was 26.1 and 40.3 m, respectively (p = 0.06 and 0.009, respectively) [&lt;ulink linkID="1929619" linkType="Reference"&gt;1929619&lt;/ulink&gt;]. In July 2017, similar data were presented at the 13th World Congress on Inflammation [&lt;ulink linkID="1945204" linkType="Reference"&gt;1945204&lt;/ulink&gt;], [&lt;ulink linkID="1947773" linkType="Reference"&gt;1947773&lt;/ulink&gt;]. In February 2018, data from the long-term follow up portion of the LARIAT study were reported. Data demonstrated that eGFR level was significantly increased in PAH patients (n = 71) after 16 weeks bardoxolone methyl compared to placebo (n = 30) by 10.6 ml/min/1.73 m2 (p &amp;lt; 0.0001). After 16 weeks of treatment, 55 patients on 56 weeks of treatment and 26 patients on 104 weeks of treatment had experienced significant mean increase in eGFR by 10.7 and 11.3 ml/min/1.73 m2 from baseline, respectively (p &amp;lt; 0.0001). Further, 88% of patients on bardoxolone maintained increase in eGFR above baseline after two years of treatment. The LARIAT PAH patients had a median time since diagnosis of 3.3 years (n = 101; 66 weeks median duration of treatment). Also, observed that patients who had treated with bardoxolone for at least one year had a persisting improvement in kidney function versus placebo, even after the drug was withdrawn for one month [&lt;ulink linkID="2004663" linkType="Reference"&gt;2004663&lt;/ulink&gt;]. In March 2018, data were reported in patients with interstitial lung disease (8 patients with IPF and 25 with sarcoidosis) which demonstrated that patients with IPF saw a significant improvement after 16 weeks of treatment  with an  increase in 6MWD from baseline of 38 m (p &amp;lt; 0.05) while patients in the placebo group had a non-significant reduction of 13 m. Patients with sarcoidosis also demonstrated a significant increase in 6MWD at week 16 from baseline of 17 m (p &amp;lt; 0.05) while patients in the placebo group had a non-significant increase of 9 m [&lt;ulink linkID="2016546" linkType="Reference"&gt;2016546&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;In July 2007, a phase II trial for RA was underway [&lt;ulink linkID="811461" linkType="Reference"&gt;811461&lt;/ulink&gt;]; however, no further development has since been reported. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumor&lt;/subtitle&gt;By January 2010, an open-label, non-randomized, single group assignment, dose finding, pharmacokinetic, phase I trial (&lt;ulink linkID="49557" linkType="Protocol"&gt;NCT00508807&lt;/ulink&gt;; 005-0984)  in patients (n = 21) with advanced solid tumors or lymphoid malignancies had been completed in the US [&lt;ulink linkID="1260985" linkType="Reference"&gt;1260985&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, a US phase II, multicenter, randomized, open-label trial (&lt;ulink linkID="26141" linkType="Protocol"&gt;NCT00535314&lt;/ulink&gt;, RTA 402-C-0704) was planned in patients with advanced malignant melanoma (n = 60), to determine the proportion of patients without progression at 6 months. Patients would be randomly assigned to two different doses of bardoxolone methyl, to be administered orally once daily for 28 days. The trial was expected to complete in November 2008. However, by December 2007 the trial had been withdrawn prior to recruitment [&lt;ulink linkID="835809" linkType="Reference"&gt;835809&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2007, data from a phase I trial  had shown the drug to be active against  cancer and to have a good safety profile [&lt;ulink linkID="811461" linkType="Reference"&gt;811461&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, a US phase I/II trial (&lt;ulink linkID="38533" linkType="Protocol"&gt;NCT00529113&lt;/ulink&gt;, 402-C-0702) was initiated in combination with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; in patients with pancreatic cancer (n = 114). The phase I portion was a randomized, open label, single group assignment trial to determine the maximum tolerated dose of bardoxolone methyl. Bardoxolone methyl would be administered orally on days 1 to 21, while gemcitabine would be administered iv on days 1, 8, and 15 of each 28 day cycle. The phase II portion was a randomized, double-blind trial of the combination in comparison with placebo.  The drugs would be administered dependent on the phase I results [&lt;ulink linkID="834208" linkType="Reference"&gt;834208&lt;/ulink&gt;]; in December 2010, the trial was terminated to pursue other indications [&lt;ulink linkID="834208" linkType="Reference"&gt;834208&lt;/ulink&gt;]; in March 2018, it was reported that bardoxolone methyl improved  kidney function as measured by eGFR (increase of 32.2 eFRG ml/min/1.73mm2) [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;By October 2005, an IND was expected to be filed at the end of the year [&lt;ulink linkID="627604" linkType="Reference"&gt;627604&lt;/ulink&gt;]. In November 2005, a phase I solid tumor study was planned for 1Q06 [&lt;ulink linkID="632672" linkType="Reference"&gt;632672&lt;/ulink&gt;]. In April 2006, a US phase I, open label, dose-escalating trial (&lt;ulink linkID="28752" linkType="Protocol"&gt;NCT00529438&lt;/ulink&gt;, 402-C-0501) was initiated in patients with advanced solid tumors or lymphoid malignancies [&lt;ulink linkID="852962" linkType="Reference"&gt;852962&lt;/ulink&gt;]. In October 2007,  data from the trial were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA. Patients (n = 30) received bardoxolone methyl at ten dose levels (5 to 1300 mg/day po) on the first 21 days of a 28-day cycle. Dose-limiting toxicity (grade 3 liver transaminase elevations) was observed in two patients at the 1300 mg/day dose. At doses above 900 mg/day occasional fatigue and anorexia were reported. The mean biological half-life of bardoxolone methyl was 31 h. Of 12 evaluable patients, a partial response was observed in 1 patient with anaplastic thyroid cancer receiving the 1300 mg/day dose and stable disease was reported in 1 patient with melanoma receiving the same dose [&lt;ulink linkID="843849" linkType="Reference"&gt;843849&lt;/ulink&gt;]; bardoxolone methyl improved  kidney function as measured by eGFR (increase of 18.2 eFRG ml/min/1.73mm2) [&lt;ulink linkID="2011323" linkType="Reference"&gt;2011323&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;By January 2012, an open-label, phase I trial (&lt;ulink linkID="84066" linkType="Protocol"&gt;NCT01503866&lt;/ulink&gt;; 402-C-1003) to assess pharmacokinetics in healthy subjects had been completed in the US [&lt;ulink linkID="1260978" linkType="Reference"&gt;1260978&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011,  a randomized, single-dose, open-label, double blind, phase I trial (&lt;ulink linkID="82048" linkType="Protocol"&gt;NCT01461161&lt;/ulink&gt;; 402-C-1004) in healthy subjects (expected n = 32) was initiated in the US [&lt;ulink linkID="1260971" linkType="Reference"&gt;1260971&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, a phase  I/II randomized, double blind, placebo control, multiple, dose-escalation trial (&lt;ulink linkID="18161" linkType="Protocol"&gt;NCT00550849&lt;/ulink&gt;, RTA 402-C-0701) was initiated in patients with hepatic dysfunction (n = 16). Three groups of eight patients each would  be enrolled, with six patients randomized to bardoxolone methyl (5, 25, and 50 mg) and two to placebo; however, the trial was terminated in  November 2007 after the second cohort was completed [&lt;ulink linkID="852967" linkType="Reference"&gt;852967&lt;/ulink&gt;]. By March 2009, encouraging results had been observed   [&lt;ulink linkID="995007" linkType="Reference"&gt;995007&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In  October 2018, preclinical data were presented at the 2018 ASN Kidney Week in San Diego, CA. Bardoxolone methyl increased Nrf2 activity, improved mitochondrial function, and reduced inflammation in renal cell lines derived from patients with ADPKD [&lt;ulink linkID="2085062" linkType="Reference"&gt;2085062&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2017, in vitro data were presented at the 2017 ATS International Conference in Washington DC. Human pulmonary arterial smooth muscle cells (PASMCs) exhibited an increase in expression HIFI target genes like GLUT1 and VEGF due to hypoxia; and by incorporation of bromodeoxyuridine, hypoxia caused a significant increase in PASMC proliferation (p &amp;lt; 0.05). This PASMC proliferation under hypoxic conditions was significantly reduced after treatment with bardoxolone methyl (p &amp;lt; 0.001). Also, bardoxolone methyl treatment in PASMCs exhibited an increase in the expression of Nrf2 target genes like NQO1 and GCLM; while the expression and secretion of MCP1 (CCL2) was suppressed with a reduction in the levels of MCP1 mRNA and protein (p &amp;lt; 0.001) [&lt;ulink linkID="1929616" linkType="Reference"&gt;1929616&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were reported. Data demonstrated that bardoxolone methyl improved mitochondrial function and energy production in the skeletal muscle without affecting systemic hemodynamics. Furthermore, Nrf2 pathway activation regulated multiple genes that promote the production of cellular energy within the mitochondria and facilitates mitochondrial homeostasis and efficiency. Also, Bardoxolone demonstrated activity in preclinical models of lupus and scleroderma [&lt;ulink linkID="1696511" linkType="Reference"&gt;1696511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, data were presented at the 94th Annual Meeting of the Endocrine Society in Houston, TX. In uninephrectomized db/db mice, bardoxolone methyl was found to induce NRF2 gene expression, Nqo1, in kidney. A trend towards multiple renal morphological changes (decreased mesangial matrix expansion, decreased periglomerular fibrosis, decreased glomerular necrosis, and increased tubular regeneration/degeneration) was observed in bardoxolone-treated mice. Bardoxolone was not associated with improvement in measures of renal structure or renal function [&lt;ulink linkID="1303145" linkType="Reference"&gt;1303145&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, preclinical data were presented at the 50th ASH meeting in San Francisco, CA. bardoxolone methyl significantly affected normal hematopoietic cells including precursor populations in vivo and promoted granulopoiesis in non-irradiated mice [&lt;ulink linkID="967702" linkType="Reference"&gt;967702&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data on bardoxolone methyl were presented at the 99th AACR annual meeting in San Diego, CA, showing that it ameliorated the symptoms and  effects of lymphoproliferative autoimmunity in mice engineered to develop the condition at between 4 and 6 months of age [&lt;ulink linkID="895230" linkType="Reference"&gt;895230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, preclinical data were presented at the annual meeting of the Multinational Association of Supportive Care in Cancer in St Gallen, Switzerland. Bardoxolone methyl protected normal tissue from radiotherapy injury and enhanced the effect of the radiation on tumor cells, according to data from a rat human lung cancer xenograft model [&lt;ulink linkID="810051" linkType="Reference"&gt;810051&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, preclinical data were presented at the 98th AACR meeting in Los Angeles, CA. Bardoxolone methyl was found to inactivate of Stat3 suggesting the agent could be used as a breast cancer therapy. In 4T1 cells treated with bardoxolone methyl (500 nM) the following were observed: inactivation of Stat3, Src and Akt; 4-fold reduction of c-Myc mRNA levels; accumulation of cells in G2M cell cycle phase; abrogation of invasive growth; lack of apoptosis induction. Also, bardoxolone methyl inhibited breast cancer growth and lung metastases, and restored splenic mature dendritic cells (DCs) in vivo [&lt;ulink linkID="780196" linkType="Reference"&gt;780196&lt;/ulink&gt;]. Further data presented at the meeting indicated that bardoxolone methyl inhibited the IL-6-Stat3 pathway, and reversed &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; and cisplatin resistance in drug-resistant ovarian cancer cell lines [&lt;ulink linkID="783537" linkType="Reference"&gt;783537&lt;/ulink&gt;]. Similar data were published in May 2007 [&lt;ulink linkID="795236" linkType="Reference"&gt;795236&lt;/ulink&gt;], [&lt;ulink linkID="795004" linkType="Reference"&gt;795004&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, preclinical data were presented at the 18th EORTC-NCI-AACR meeting in Prague, Czech Republic. To determine whether the drug could enhance the effects of radiation while protecting normal GI mucosal tissue from radiation-induced damage, mice with NSCLC xenografts were treated with two or three fractions of 5 or 4 Gy, and bardoxolone methyl [&lt;ulink linkID="742575" linkType="Reference"&gt;742575&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006,  preclinical data were presented at the AACR Frontiers in Cancer Prevention Meeting  in Boston, MA. Bardoxolone methyl reduced tumor burden by 99% in mice exposed to the lung cancer-inducer, vinyl carbamate. The mice had one fifth the number of tumors, which  were smaller and less invasive than the control mice who did not receive bardoxolone methyl [&lt;ulink linkID="742803" linkType="Reference"&gt;742803&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2006, bardoxolone methyl had been shown to cause minimal toxicity in non-human primates when administered orally at very high doses, and to be well absorbed and to reach high concentrations in various tissues [&lt;ulink linkID="660489" linkType="Reference"&gt;660489&lt;/ulink&gt;], [&lt;ulink linkID="660802" linkType="Reference"&gt;660802&lt;/ulink&gt;]. Similar data were presented in November 2006 at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague, Czech Republic [&lt;ulink linkID="739557" linkType="Reference"&gt;739557&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2006, preclinical studies had shown that bardoxolone methyl inhibited IkB alpha kinase (IKK) in human leukemia cell lines and cancer patient tissue samples, resulting in the suppression of both constitutive and inducible forms of NF-kB. Bardoxolone methyl inhibited NF-kB in cells activated by TNF, IL-1 beta, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke, and its inhibition of IKK correlated with suppression of antiapoptotic genes (IAP2, cFLIP, TRAF1, survivin, and bcl- 2), proliferation genes (cyclin D1, COX-2, and c-myc), and angiogenesis genes (VEGF and MMP-9). The drug suppressed NF-kB activation induced by cisplatin, doxorubicin, and Taxol and enhanced their cytotoxic effects [&lt;ulink linkID="660575" linkType="Reference"&gt;660575&lt;/ulink&gt;], [&lt;ulink linkID="660489" linkType="Reference"&gt;660489&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, preclinical data on &lt;ulink linkID="26563" linkType="Drug"&gt;RTA-401&lt;/ulink&gt; and bardoxolone methyl were presented at the 17th AACR-NCI-EORTC meeting in Philadelphia, PA. The in vitro effect of HER2 overexpression on sensitivity of breast cancer cells to RTA-401 and bardoxolone methyl was determined both in vivo and in vitro. In vitro, RTA-401 dose-dependently inhibited HER2 phosphorylation in HER2 overexpressing cells. It also induced transactivation of PPAR gamma in both vector control and HER2 transfected MCF7 cells.  Growth inhibition at low doses correlated with induction of caveolin-1, a tumor suppressor gene, and reduced cyclin D1 mRNA expression.  In vivo, both lipid encapsulated RTA-401 and bardoxolone methyl gave similarly potent activity in MCF7/HER2 xenograft model [&lt;ulink linkID="637270" linkType="Reference"&gt;637270&lt;/ulink&gt;]. The cytoprotective efficacy of RTA-401 and bardoxolone methyl were assessed in hamster models of radiation-induced mucositis.  The primary end-point being number of days with mucositis scores of 3 or more (D3+).  In the first study, RTA-401 (10 mg/kg  bid) on day 1 to 7 reduced D3+ by 55%, and bardoxolone methyl (6.5 mg/kg bid) on day 1 to 5 reduced D3+ by 35%. In a second study, the same dose and schedule of bardoxolone methyl produced a 38% reduction in D3+ [&lt;ulink linkID="638297" linkType="Reference"&gt;638297&lt;/ulink&gt;]. Bardoxolone methyl (4 mg/kg po bid for 19 days) inhibited tumor growth in a 4T1 breast cancer xenograft model. Combinations of bardoxolone methyl and doxorubicin or &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; inhibited growth to a greater extent than any single agent [&lt;ulink linkID="637297" linkType="Reference"&gt;637297&lt;/ulink&gt;]. Similar data were presented at the 18th EORTC-NCI-AACR meeting in Prague, Czech Republic in November 2006 [&lt;ulink linkID="745471" linkType="Reference"&gt;745471&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Bardoxolone methyl demonstrated superior activity to doxorubicin in an animal model of stage IV breast cancer, superior inhibition of tumor growth in a model of pancreatic cancer and has been shown to inhibit angiogenesis in an in vivo model [&lt;ulink linkID="627604" linkType="Reference"&gt;627604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2005, research was published showing that &lt;ulink linkID="26563" linkType="Drug"&gt;RTA-401&lt;/ulink&gt;, bardoxolone methyl and CDDO-Im inhibited proliferation of SW-480, HCT-116 and HT-29 colon cancer cells at low concentrations, and at higher concentrations induced apoptosis. Antiproliferative effects appeared to be via induction of the tumor suppressor gene caveolin-1 [&lt;ulink linkID="628551" linkType="Reference"&gt;628551&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, preclinical data on bardoxolone methyl were presented at the 46th ASH meeting in San Diego, CA. The effects of bardoxolone methyl on CD34+ acute myeloid leukemia (AML) progenitor cells were examined in vitro. Exposure to 1 microM bardoxolone methyl induced apoptosis in all but one AML sample. SCID mice injected iv with U937 cells were treated with liposomally-delivered bardoxolone methyl (20mg/kg/day iv every other day, starting at day 7, for a total of 9 injections). Bardoxolone methyl was not toxic, but pathological and flow cytometry analysis showed reduced leukemia burden (by 55 to 86%) in the bone marrow, liver, and spleen of mice. Bardoxolone methyl also inhibited ERK phosphorylation in 9 of 15 acute lymphoid leukemia patient samples and promoted apoptosis [&lt;ulink linkID="573845" linkType="Reference"&gt;573845&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2004, research was published in which bardoxolone methyl was found to activate caspase-8 and induce expression of death receptors (DRs), particularly DR-5, in human lung cancer cells via activation of the JNK pathway [&lt;ulink linkID="628613" linkType="Reference"&gt;628613&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, preclinical data on bardoxolone methyl were presented at the 94th AACR meeting, Washington, DC. The activity of bardoxolone methyl was evaluated in six leukemia cell lines and was found to be nearly maximally active after very brief exposures [&lt;ulink linkID="497731" linkType="reference"&gt;497731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2002, research was published indicating that bardoxolone methyl was a potent inducer of apoptosis in human non-small-cell lung carcinoma (NSCLC) cells with IC50 values of between 0.1 and 0.3 microM. Apoptosis was believed to occur via a cytochrome c-triggered caspase activation pathway and was not related to Bcl-2 expression [&lt;ulink linkID="628540" linkType="Reference"&gt;628540&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2001, data were presented at the 43rd ASH meeting in Orlando, FL. Bardoxolone methyl induced apoptosis in AML cells (ED50 =  0.5 microM) and at 0.3 microM the compound sensitized the cells to the death ligand TRAIL [&lt;ulink linkID="431548" linkType="reference"&gt;431548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2000, research was published indicating that RTA-401 and bardoxolone methyl inhibit the organization of the bone marrow endothelium into capillary-like structures. Complete inhibition was observed in patients with acute lymphoblastic leukemia (ALL) and normal donors at 1 microM RTA-401 and 0.3 microM bardoxolone methyl. The agents' inhibitory effects are not mediated by apoptosis induction, since no significant inhibition was observed at timepoints at which endothelial effects were abrogated, but apoptosis was observed at later timepoints. In a murine angiogenesis assay, bardoxolone methyl (0.5 microM), but not RTA-401 (1.0 microM), prevented angiogenic invasion of implanted Matrigel promoted by ALL BM plasma. Bardoxolone methyl thus abrogates de novo angiogenesis promoted by ALL [&lt;ulink linkID="393336" linkType="reference"&gt;393336&lt;/ulink&gt;]. Bardoxolone methyl induced differentiation and growth inhibition in myeloid leukemia cells and primary acute myeloid leukemia samples; this effect is markedly increased by combination with retinoids [&lt;ulink linkID="393493" linkType="reference"&gt;393493&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1999, research was published indicating that bardoxolone methyl had potent antiproliferative and anti-apoptotic activity against AML [&lt;ulink linkID="350499" linkType="Reference"&gt;350499&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3077">Alport syndrome</Indication><StatusDate>2017-03-02T00:00:00.000Z</StatusDate><Source id="1892509" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2018-05-31T00:00:00.000Z</StatusDate><Source id="2040730" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3077">Alport syndrome</Indication><StatusDate>2017-03-02T00:00:00.000Z</StatusDate><Source id="1892509" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3077">Alport syndrome</Indication><StatusDate>2017-03-02T00:00:00.000Z</StatusDate><Source id="1892509" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3077">Alport syndrome</Indication><StatusDate>2017-03-02T00:00:00.000Z</StatusDate><Source id="1892509" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3077">Alport syndrome</Indication><StatusDate>2017-03-02T00:00:00.000Z</StatusDate><Source id="1892509" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2011-06-16T00:00:00.000Z</StatusDate><Source id="1200759" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2300">Autosomal dominant polycystic kidney disease</Indication><StatusDate>2019-05-30T00:00:00.000Z</StatusDate><Source id="2157782" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3077">Alport syndrome</Indication><StatusDate>2017-03-02T00:00:00.000Z</StatusDate><Source id="1892509" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3084">Focal segmental glomerulosclerosis</Indication><StatusDate>2017-12-31T00:00:00.000Z</StatusDate><Source id="1995262" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3076">IgA nephropathy</Indication><StatusDate>2017-12-31T00:00:00.000Z</StatusDate><Source id="1995262" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2012-10-17T00:00:00.000Z</StatusDate><Source id="1333148" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2012-10-17T00:00:00.000Z</StatusDate><Source id="1333148" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-01-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2012-10-17T00:00:00.000Z</StatusDate><Source id="1333148" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-01-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2012-10-17T00:00:00.000Z</StatusDate><Source id="1333148" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2007-12-06T00:00:00.000Z</StatusDate><Source id="835809" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-01-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-01-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2012-10-17T00:00:00.000Z</StatusDate><Source id="1333148" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-01-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="249">Pancreas tumor</Indication><StatusDate>2010-12-01T00:00:00.000Z</StatusDate><Source id="834208" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-01-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-02-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1263">Mucositis</Indication><StatusDate>2012-02-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate>2010-09-30T00:00:00.000Z</StatusDate><Source id="1910389" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20565">Dartmouth College</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-11-01T00:00:00.000Z</StatusDate><Source id="567993" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23382">MD Anderson Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-11-01T00:00:00.000Z</StatusDate><Source id="567993" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate>2007-03-31T00:00:00.000Z</StatusDate><Source id="834208" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1263">Mucositis</Indication><StatusDate>2005-10-10T00:00:00.000Z</StatusDate><Source id="627604" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2007-07-06T00:00:00.000Z</StatusDate><Source id="811461" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2011-06-16T00:00:00.000Z</StatusDate><Source id="1200759" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2011-06-16T00:00:00.000Z</StatusDate><Source id="1200759" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2011-06-16T00:00:00.000Z</StatusDate><Source id="1200759" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2011-06-16T00:00:00.000Z</StatusDate><Source id="1200759" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2011-06-16T00:00:00.000Z</StatusDate><Source id="1200759" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1519397" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1519397" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate>2010-09-30T00:00:00.000Z</StatusDate><Source id="1910389" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1867">Pulmonary hypertension</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1766937" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1519397" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3510">Pulmonary artery hypertension</Indication><StatusDate>2016-09-21T00:00:00.000Z</StatusDate><Source id="1799354" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2012-02-29T00:00:00.000Z</StatusDate><Source id="1308643" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2008-04-18T00:00:00.000Z</StatusDate><Source id="905520" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2300">Autosomal dominant polycystic kidney disease</Indication><StatusDate>2017-12-31T00:00:00.000Z</StatusDate><Source id="1995262" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20565">Dartmouth College</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>1999-12-17T00:00:00.000Z</StatusDate><Source id="350499" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23382">MD Anderson Cancer Center</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>1999-12-17T00:00:00.000Z</StatusDate><Source id="350499" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-11-01T00:00:00.000Z</StatusDate><Source id="567993" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2005-10-10T00:00:00.000Z</StatusDate><Source id="627604" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2006-04-30T00:00:00.000Z</StatusDate><Source id="852962" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003618">Reata Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2007-09-24T00:00:00.000Z</StatusDate><Source id="835809" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="100">Diabetic nephropathy</Indication><StatusDate>2010-09-30T00:00:00.000Z</StatusDate><Source id="1910389" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1003618">Reata Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="2300">Autosomal dominant polycystic kidney disease</Indication><AwardedIndication>Treatment of autosomal dominant polycystic kidney disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-06-05T00:00:00.000Z</MileStoneDate><Source id="2159660" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1003618">Reata Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3077">Alport syndrome</Indication><AwardedIndication>Treatment of Alport syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-05-25T00:00:00.000Z</MileStoneDate><Source id="2040411" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1003618">Reata Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3077">Alport syndrome</Indication><AwardedIndication>Treatment of Alport syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-04-19T00:00:00.000Z</MileStoneDate><Source id="2028500" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1003618">Reata Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3077">Alport syndrome</Indication><AwardedIndication>Treatment of Alport syndrome</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-07-03T00:00:00.000Z</MileStoneDate><Source id="1943942" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1003618">Reata Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3510">Pulmonary artery hypertension</Indication><AwardedIndication>Treatment of pulmonary arterial hypertension</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-03-30T00:00:00.000Z</MileStoneDate><Source id="1647928" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1003618">Reata Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2008-06-08T00:00:00.000Z</MileStoneDate><Source id="952903" type="PR"/></Row><Row><RegulatoryDesignation id="14">Sakigake</RegulatoryDesignation><OwnerCompany id="1037687">Kirin Holdings Co Ltd</OwnerCompany><Country id="JP">Japan</Country><Indication id="100">Diabetic nephropathy</Indication><AwardedIndication>Treatment of diabetic nephropathy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-03-27T00:00:00.000Z</MileStoneDate><Source id="2017541" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-01769"><Name>STAT3 gene</Name><SwissprotNumbers/></Target><Target id="GTGT-04576"><Name>NFE2L2 gene</Name><SwissprotNumbers/></Target><Target id="PTGT-00981"><Name>I-kappa B kinase</Name><SwissprotNumbers/></Target><Target id="PTGT-01442"><Name>Nuclear factor kappa B</Name><SwissprotNumbers/></Target><Target id="PTGT-08848"><Name>Kelch like ECH associated protein 1</Name><SwissprotNumbers><Swissprot>P57790</Swissprot><Swissprot>Q14145</Swissprot><Swissprot>Q5R774</Swissprot><Swissprot>Q684M4</Swissprot><Swissprot>Q9Z2X8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1003618">Reata Pharmaceuticals Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="1037687">Kirin Holdings Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20565">Dartmouth College</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC</Smiles><Smiles>C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)O</Smiles></StructureSmiles><Deals><Deal id="107431" title="Reata to develop Dartmouth College's RTA-401 and RTA-402 worldwide"/><Deal id="110536" title="Reata to develop MD Anderson Cancer Center's series ofanticancer compounds worldwide "/><Deal id="129232" title="Kyowa Hakko Kirin to develop Reata's bardoxolone in Japan, China, Taiwan, Korea, and Southeast Asia       "/><Deal id="132042" title="Abbott to develop Reata's bardoxolone methyl for chronic kidney disease excluding the US and Asia      "/></Deals><PatentFamilies><PatentFamily id="1186706" number="WO-2011130302" title="Method of treating obesity using antioxidant inflammation modulators"/><PatentFamily id="1886122" number="WO-2009023232" title="Novel forms of CDDO methyl ester"/><PatentFamily id="2631312" number="WO-2013169553" title="Method for synthesizing 2-cyano-3,12-dioxoolean-1,9(11)-dien-28-oic acid methyl ester and derivatives thereof"/><PatentFamily id="4051152" number="WO-2018089539" title="Methods of treating alport syndrome using bardoxolone methyl or analogs thereof"/><PatentFamily id="49096" number="WO-2010093944" title="Delayed release, oral dosage compositions that contain amorphous cddo-me"/><PatentFamily id="689811" number="WO-09965478" title="Therapeutic compositions and methods of use"/><PatentFamily id="885510" number="WO-2009089545" title="Synthetic triterpenoids and methods of use in the treatment of disease"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Reata Pharmaceuticals Inc" id="1003618"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kirin Holdings Co Ltd" id="1037687"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SimplicityBio" id="1138237"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dartmouth College" id="20565"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>